

1 **Modifiable Risk Factors for Stroke, Dementia, and Late-Life Depression: A Systematic Review**
2 **and DALY Weighted Risk Factors for a Composite Outcome**

3

4 Jasper R. Senff, MD¹⁻⁵; Reinier W.P. Tack, MD¹⁻⁵, Akashleena Mallick, MD¹⁻⁴, Leidys Gutierrez-
5 Martinez, MD MSc¹⁻⁴, Jonathan Duskin MD^{1-4,14}, Tamara N. Kimball MD¹⁻⁴, Zeina Chemali MD
6 MPH^{1,2,6}, Amy Newhouse MD^{1,7}, Christina Kourkoulis BS¹⁻⁴, Cyprien Rivier MD^{8,9}, Guido J Falcone
7 MD ScD MPH^{8,9}, Kevin N Sheth MD PhD^{8,9}, Ronald M Lazar MD PhD¹⁰, Sarah Ibrahim RN PhD<sup>11-
8 12</sup>, Aleksandra Pikula MD¹³⁻¹⁵, Rudolph E. Tanzi¹ PhD, Gregory Fricchione MD PhD^{1,16}, H. Bart
9 Brouwers MD PhD⁵, Gabrél J.E. Rinkel MD PhD FRCP Edin⁵, Nirupama Yechoor MD¹⁻⁴, Jonathan
10 Rosand, MD MSc¹⁻⁴; Christopher D. Anderson* MD MMsc^{1-4,16}, Sanjula D. Singh*, MD PhD MSc¹⁻⁵

11

12 **Affiliations:**

- 13 1. Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston,
14 MA, USA
- 15 2. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
- 16 3. Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 17 4. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- 18 5. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical
19 Center Utrecht, Utrecht, NL
- 20 6. Division of Neuropsychiatry, Massachusetts General Hospital, Boston, MA, United States
- 21 7. Department of Medicine, Massachusetts General Hospital, Boston, MA, United States,
- 22 8. Department of Neurology, Yale School of Medicine, New Haven, CT, USA
- 23 9. Yale Center for Brain and Mind Health, Yale School of Medicine, New Haven, CT, USA
- 24 10. McKnight Brain Institute, Department of Neurology, School of Medicine, University of Alabama
25 School of Medicine, Birmingham, AL, United States
- 26 11. Program for Health System and Technology Evaluation, Toronto General Hospital Research
27 Institute, Department of Neurology, Toronto Western Hospital
- 28 12. Centre for Advancing Collaborative Healthcare & Education (CACHE), University of Toronto

- 29 13. Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada,
30 14. Jay and Sari Sonshine Centre for Stroke Prevention and Cerebrovascular Brain Health, Krembil
31 Brain Institute, University Health Network, Toronto, ON, Canada
32 15. Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada
33 16. Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA
34 * Contributed equally to this manuscript.

35 **Running head:** Modifiable Risk Factors for Brain Disease

36 **Corresponding author:**

- 37 - Sanjula Dhillon Singh
38 - Email address: ssingh32@mgh.harvard.edu
39 - Address: McCance Center for Brain Health, Massachusetts General Hospital, Harvard
40 Medical School, 399 Revolution Drive, Somerville, MA 02145, United States of America

41

42	Title character count:	146	No. of references:	159
43	Word count abstract:	250	No. of tables:	2 (7 supplementary)
44	Word count article:	3493	No. of figures:	4 (1 supplementary)

45

Abstract

46

47 **Background:** At least 60% of stroke, 40% of dementia, and 35% of late-life depression (LLD) are
48 attributable to modifiable risk factors, with great overlap due to a shared underlying pathophysiology.
49 This study aims to systematically identify overlapping risk factors for these diseases and calculate
50 their relative impact on a composite outcome.

51 **Methods:** A systematic literature review was performed in Pubmed, Embase, and PsycInfo, between
52 January 2000 and September 2023. We included meta-analyses reporting effect sizes of modifiable
53 risk factors on the incidence of stroke, dementia, and/or LLD. The most relevant meta-analyses were
54 selected, and Disability Adjusted Life Year (DALY) weighted beta-coefficients were calculated for a
55 composite outcome. The beta-coefficients were then normalized to assess relative impact.

56 **Results:** Our search yielded 182 meta-analyses meeting the inclusion criteria, of which 59 were
57 selected to calculate DALY-weighted risk factors for a composite outcome. Identified risk factors
58 included alcohol use (normalized beta-coefficient highest category: -20), blood pressure (87), BMI
59 (42), fasting plasma glucose (57), total cholesterol (14), leisure time cognitive activity (-54),
60 depressive symptoms (34), diet (27), hearing loss (35), kidney function (60), pain (25), physical
61 activity (-34), purpose in life (-30), sleep (44), smoking (58), social engagement (32), and stress (32).

62 **Discussion:** This study identified overlapping modifiable risk factors and calculated the relative
63 impact of these factors on the risk of a composite outcome of stroke, dementia, and LLD. These
64 findings could guide preventative strategies and serve as an empirical foundation for future
65 development of tools that can empower people to reduce their risk of these diseases.

66

67 **Funding:** US National Institutes of Health and American Heart Association.

68

Introduction

69 Neurological disorders are the leading cause of disability-adjusted life years (DALYs) worldwide¹.
70 This is largely contributed by stroke (>143 million DALYs), dementia (>25 million DALYs), and
71 depression (>37 million DALYs)². Research indicates that at least 60% of strokes, 40% of dementia,
72 and 35% of late-life depression (LLD) cases could be prevented or slowed down toward the limit of
73 human life span through adequate risk factor control³⁻⁶. Epidemiological studies demonstrate that risk
74 factors such as blood pressure, blood sugar, cholesterol, diet, body mass index (BMI), physical
75 activity, smoking, and social isolation are shared among these age-related brain diseases^{1,7-10}. This
76 overlap in risk factors is, at least partially, attributable to the shared underlying pathophysiology of
77 neurodegenerative and cerebrovascular disease, including cerebral small vessel disease (CSVD) –
78 with multifaceted impact on cerebral circulation and brain integrity^{11,12}.

79

80 Evidence-based tools, such as models or scores, can empower, educate, and motivate both patients
81 and practitioners to facilitate behavioral changes that reduce modifiable risk factors for age-related
82 brain diseases¹³. However, the currently available tools that address modifiable risk factors have
83 limitations. Most existing tools for dementia, stroke, and LLD mostly focus on risk stratification of
84 individual brain diseases¹⁴⁻²³ or together with cardiovascular disease¹⁰, lacking a holistic approach
85 that addresses the shared underlying pathophysiology. In line with the recommendations of the
86 American Heart Association (AHA) and the American Academy of Neurology (AAN)^{10,24,25}, there is a
87 need to develop, optimize, and implement novel and practical tools that address modifiable risk
88 factors to substantiate preventive neurology in both primary care and specialized medical care
89 worldwide.

90

91 While there are overlapping risk factors for stroke, dementia, and LLD, these factors have varying
92 impacts on each disease^{1,7-10}. To develop effective tools for addressing age-related brain diseases
93 holistically, it is crucial to first understand how overlapping risk factors differentially impact the

94 incidence and burden (expressed in DALYs) of these diseases, which is currently a gap in the
95 available literature.

96 Therefore, this study aims to identify overlapping risk factors, obtain the most relevant effect sizes,
97 and calculate their DALY-weighted effect on a composite outcome of stroke, dementia, and LLD.

98 **Methods**

99

100 **Study design**

101 The study design, registered in PROSPERO (identifier: CRD42023476939), is illustrated in Figure 1.

102 The systematic review of the literature was conducted in line with the Joanna Briggs Institute and

103 PRISMA guidelines^{26,27}. The search design was based on a PEO (Population, Exposure, Outcome)

104 format²⁸.

105

106 **Systematic review of risk models: identifying overlapping risk factors**

107 One authors (JRS) searched PubMed and Embase from January 2000 to July 2023 (Table S1).

108 Inclusion criteria were: (i) indexed reviews, guidelines, development, and validation studies, (ii)

109 studies describing risk models for stroke, dementia, and/or LLD, (ii) models validated with a

110 predictive value with a c-statistic of ≥ 0.70 ²⁹, and (iii) models including modifiable risk factors. We

111 included the most recently validated iteration of any model. Exclusion criteria were: (i) models made

112 for a disease-specific population (e.g., stroke risk in patients with atrial fibrillation) and (ii) machine

113 learning models³⁰. Data extraction included author, publication year, model details, cohort details,

114 statistical analysis, risk factors, and outcomes. We selected modifiable risk factors overlapping in at

115 least two diseases for the systematic review of meta-analyses.

116

117 **Systematic review of meta-analyses: obtaining effect sizes of individual diseases per risk factor**

118

119 Search strategy

120 A search was conducted in PubMed, Embase, and PsycInfo between January 2000 and September

121 2023, by two authors: JRS and RWPT (Table S2). Included exposures were the modifiable risk

122 factors previously identified. The outcomes were defined as the incidence of all cause-dementia

123 (including Alzheimer's disease, vascular dementia, and/or all dementia), stroke (including both

124 ischemic and hemorrhagic stroke) and/or LLD. Both authors performed title and abstract screening
125 and full-text analyses independently from each other. Disagreements were resolved in a consensus
126 meeting with a third reviewer (SDS). The study selection was performed using Covidence (Covidence
127 Systematic Review Software Veritas Health Innovation, Melbourne, Australia)³¹.

128

129 Inclusion- and exclusion criteria

130 The inclusion criteria were: (i) meta-analyses of observational studies, (ii) written in English, (iii)
131 describing a disease-risk factor relationship expressed as an effect size (Relative Risk [RR], Odds
132 Ratio [OR] or Hazard Ratio [HR]), and (iv) risk factors defined as a dichotomized or categorical
133 variable. Restriction to meta-analyses ensured a well-powered and feasible overview of the current
134 literature³², while restriction to dichotomized or categorized ensured clinical applicability³³. For the
135 dietary components, we included factors as stated (either recommended or contraindicated) by the
136 AHA and the Dietary Approaches to Stop Hypertension (DASH)^{10,34}. Our exclusion criteria included:
137 (i) disease-specific populations (e.g., patients with atrial fibrillation) (ii) treatments (e.g., cholesterol
138 levels in statin treatment), and (iii) composite outcomes (e.g., cardiovascular disease instead of stroke)
139 or subtypes of the outcomes (e.g., ischemic stroke only).

140

141 Data extraction

142 Data extract was performed by one of two authors, JRS and RWPT. Extracted data included first
143 author, year of publication, exposure definition, outcome definition, effect size including 95%
144 confidence interval (CI), number of included studies in meta-analyses, total sample size, number of
145 outcomes, level of heterogeneity (I^2), risk of bias (ROB) tool (e.g., Newcastle-Ottawa Scale), ROB
146 assessment, and publication bias (Egger's test, Begg's test, funnel plot).

147

148 Study selection to identify the most relevant effect sizes

149 Study selection to identify the most relevant effect sizes was performed by two authors (JRS and
150 RWPT) individually. Disagreements were resolved in a consensus meeting. For each factor, the most
151 recent meta-analysis was included. Exceptions were made if an earlier meta-analysis had a sample

152 size at least 20% larger. If two meta-analysis had similar sample size selection was based on a
153 difference in quality assessed through heterogeneity level, ROB assessment, and publication bias. The
154 initial selection was based on studies that reported RR. If no studies reporting RR were available,
155 studies reporting HR, or if not available OR, were selected.

156

157 **DALY weighted risk factors for a composite outcome**

158 Risk factor definition

159 Risk factors cut-offs aligned with the AHA guidelines and Life's Essential 8 where available¹⁰.

160

161 Statistical Analysis

162 Table S4 shows the statistical methodology. To standardize effect sizes and corresponding 95%
163 confidence interval (CI) we transformed HR and OR to RR based on the disease-specific incidence
164 rates (r)³⁵. We obtained disease-specific DALYs using the most recent incidence rates from the Global
165 Burden of Disease study 2019 : "Stroke" (157.99 per 100,000), "Alzheimer diseases and other related
166 dementias" (93.52 per 100,000), and "Major Depressive Disorder" (3551.60 per 100,000)². To
167 calculate weighted effect size for a composite outcome of stroke, dementia, and LLD, the relative
168 risks with corresponding 95% CI for each risk factor category were weighted according to their
169 attributed burden, expressed in DALYs (stroke: 5.654%, dementia: 0.997%, LLD: 1.461%)². If there
170 was no effect size for a certain disease-risk factor relationship, the disease was not included in the
171 weighting. The relative risks that remained significant after calculating the composite effect size were
172 log transferred into beta (β) coefficients. To enhance interpretation and assess the relative impact of
173 the risk factors on a composite outcome, we normalized the beta-coefficient. The lowest β -coefficient
174 was normalized to 1, scaling all other β -coefficients by the same factor¹⁵.

175

Results

176

177 **Systematic review of risk models: Identification of overlapping modifiable risk factors**

178 In total, 37 articles describing 54 risk models met inclusion criteria (Figure S1). Of the models, 36
179 (67%) were on stroke, 16 (30%) on dementia, and two (4%) for LLD; none addressed a composite
180 outcome. Table S4 provides an overview of the included models.. The models identified 18
181 modifiable factors that overlapped in at least two outcomes: (1) alcohol consumption, (2) blood
182 pressure, (3) body mass index (BMI), (4) blood sugar, (5) cholesterol, (6) cognitive activity, (7)
183 depressive symptoms, (8) diet, (9) hearing impairment, (10) kidney function, (11) pain, (12) physical
184 activity, (13) self-rated health, (14) sense of belonging, (15) sleep, (16) smoking, (17) social
185 engagement, and (18) stress.

186

187

188 **Systematic review of meta-analyses: obtaining effect sizes of individual diseases per risk factor**

189 Subsequently, our systematic review of meta-analyses yielded 182 articles that met our predefined
190 criteria, encompassing 426 effect sizes (stroke N=260 [61%], dementia N=157 [37%], LLD N=9
191 [2%]) on 17 modifiable risk factors (Figure 2). Reported effect size metrics were RRs (N=280 [66%]),
192 HRs (N=111 [26%]) and ORs (N=35 [8.2%]). All studies that met our criteria are publicly available at
193 <https://www.zotero.org/groups/5402286/sroma/collections/PY6XGESM>.

194

195 Overview of meta-analyses

196

197 *Alcohol*

198 Seven meta-analyses described alcohol intake as a risk factor. For stroke incidence, effect sizes
199 ranged from 0.80 (95%CI:0.72-0.90) – 0.89 (95%CI:0.76-1.06) for low alcohol intake (<15 gr/day),
200 0.79 (95%CI:0.69-0.91) – 1.10 (95%CI:0.97-1.24) for moderate alcohol intake (15-30 gr/day), and
201 1.19 (95%CI:0.93-1.52) – 1.64 (95%CI:1.39-1.93) for heavy alcohol intake (>30 gr/day) (reference no
202 alcohol intake)³⁶⁻⁴⁰. For dementia incidence, effect sizes ranged from 0.74 (95%CI:0.61-0.91) – 0.75

203 (95%CI:0.51-1.11) for low-, 0.58 (95%CI:0.38-0.90) – 0.74 (95%CI:0.61-0.91) for moderate-, and
204 1.00 (95%CI:0.39-2.59) – 1.84 (95%CI:1.01-3.34) for heavy alcohol intake^{41,42}. No meta-analyses
205 were found that assessed the relationship between alcohol intake and LLD incidence.

206

207 *Blood Pressure*

208 Twelve meta-analyses described blood pressure as a risk factor. For stroke incidence, effect sizes
209 ranged from 1.22 (95%CI:0.95-1.57) – 1.66 (95%CI:1.51-1.81) for low pre-hypertension (120-
210 129/80-84mmHg), 1.79 (95%CI:1.49-2.16) – 1.95 (95%CI:1.73-2.21) for high pre-hypertension (130-
211 139/85-80 mmHg) and 2.23 (95%CI:2.01-2.48) – 10.92 (95%CI:7.07-16.86) for hypertension
212 (>140/90 mmHg) (reference blood pressure < 120/80 mmHg)^{36,43-48}. For dementia incidence, effect
213 sizes for hypertension ranged from 0.98 (95%CI:0.72-1.33) – 1.41 (95%CI:1.23-1.62)⁴⁹⁻⁵². No meta-
214 analyses were found that assessed the relationship blood pressure and LLD incidence.

215

216 *Body Mass Index*

217 Fifteen meta-analyses described BMI as a risk factor. For stroke incidence, the effect size for
218 underweight (<18.5 kg/m²) was 0.93 (95%CI:0.82-1.06), for overweight (25-29.9 kg/m²) it ranged
219 from 1.18 (95%CI:0.98-1.42) - 2.01 (95%CI:1.65-2.47), and for obesity (≥30kg/m²) it ranged from
220 1.16 (95%CI:1.01-1.35) - 1.47 (95%CI:1.02-2.11) (reference BMI ranging 18.5-25kg/m²)^{36,47,48,53,54}.
221 For dementia incidence, the effect sizes for underweights ranged from 0.92 (95%CI:0.74-0.92) - 1.42
222 (95%CI:1.12-1.80), for overweight from 0.82 (95%CI:0.74-0.92) - 1.26 (95%CI:1.1-1.44), and for
223 obesity from 0.78 (95%CI:0.70-0.86) - 1.79 (95%CI:1.31-2.41)^{50,51,55-62}. No meta-analyses were found
224 that assessed the relationship BMI and LLD incidence.

225

226 *Blood Sugar*

227 Six meta-analyses described blood sugar as a risk factor. For stroke incidence, effect sizes ranged
228 from 1.08 (95%CI:0.94-1.23) - 1.21 (95%CI:1.02-1.44) for prediabetic blood sugar levels (fasting
229 plasma glucose [FPG] 100-126 mg/dL), and from 1.79 (95%CI:1.68-1.91) - 2.15 (95%CI:1.76-2.63)
230 for diabetic blood sugar levels (FPG >126 mg/dL) (reference FPG <100 mg/dL)^{36,63-65}. For dementia

231 incidence, effect sizes ranged from 0.72 (95%CI:0.56-0.92) -1.22 (95%CI:1.06-1.41) for prediabetic
232 blood sugar levels, and from 1.21 (95%CI:1.06-1.37) - 1.49 (95%CI:1.10-2.03) for diabetic blood
233 sugar levels^{51,66}. No meta-analyses were found that assessed the relationship blood sugar and LLD
234 incidence.

235

236 *Cholesterol*

237 Fifteen meta-analyses described cholesterol as a risk factor. For stroke incidence, effect sizes ranged
238 from 0.99 (95%CI:0.87-1.12) – 1.14 (95%CI:1.03-1.27) for high total cholesterol, and was 1.09
239 (95%CI:0.85-1.39) for low-density lipoprotein (LDL) (reference lowest quartiles cholesterol
240 level)^{36,43,47,48,67-71}. For dementia incidence, effect sizes ranged from 1.03 (95%CI:0.74-1.43) – 1.82
241 (95%CI:1.27-2.6) for high total cholesterol^{50,51,56,72,73}. For LLD, the effect size for the presence of
242 dyslipidemia was 1.08 (95%CI:0.91-1.28)⁷⁴.

243

244 *Cognitive activity*

245 One meta-analysis described cognitive activity as a risk factor for dementia incidence, with an effect
246 size of 0.61 (95%CI:0.42-0.90) (reference no cognitive activity)⁷⁵. No meta-analyses were found that
247 assessed the relationship cognitive activity and stroke or LLD incidence.

248

249 *Depressive symptoms*

250 One meta-analysis described depressive symptoms as a risk factor for stroke incidence, with an effect
251 size of 1.36 (95%CI:1.13-1.51) (reference no depressive symptoms)⁷⁶. No meta-analyses were found
252 that assessed the relationship depressive symptoms and dementia or LLD incidence.

253

254 *Diet*

255 For stroke, a meta-analysis was included for all 11 dietary components⁷⁷⁻⁸⁷. For dementia, meta-
256 analyses for dairy, fish, sugar-sweetened beverages and saturated fats intake were retrieved and
257 included⁸⁸⁻⁹¹. No meta-analyses were found that assessed the relationship diet and LLD incidence.

258

259 *Hearing loss*

260 Three meta-analyses described hearing loss as a risk factor. The effect size was 1.33 (95%CI:1.18-
261 1.49) for stroke⁹², 1.59 (95%CI:1.37-1.86) for dementia⁹³, and 1.47 (95%CI:1.31-1.65) for LLD
262 incidence (reference no hearing loss)⁹⁴.

263

264 *Kidney Function*

265 Four meta-analyses described kidney function as a risk factor. For stroke incidence, the effect size
266 ranged from 1.07 (95%CI:0.98-1.17) - 1.10 (95%CI:1.03-1.19) for mild-, was 1.43 (95%CI:1.33-
267 1.54) for moderate- (eGFR 30-60mL/min/1.73m²) and 1.70 (95%CI:1.47-1.96) for severe kidney
268 disease (eGFR <30mL/min/1.73m²) (reference eGFR ≥90mL/min/1.73min²)^{36,95,96}. For dementia
269 incidence, the effect size was 1.14 (95%CI:1.06-1.22) for mild-, 1.31 (95%CI:0.92-1.87) for
270 moderate-, and 1.91 (95%CI:1.21-3.01) for severe kidney disease⁹⁷. No meta-analyses were found
271 that assessed the relationship depressive symptoms and LLD incidence.

272

273 *Pain*

274 One meta-analysis described the pain as a risk factor for dementia incidence, with an effect size of
275 1.26 (95%CI:1.18-1.35) (reference no pain)⁹⁸. No meta-analyses were found that assessed the
276 relationship pain and stroke or LLD incidence.

277

278 *Physical activity*

279 Eleven meta-analyses described physical activity as a risk factor. For stroke incidence, effects sizes
280 for a moderate level of physical activity ranged from 0.64 (95%CI:0.48-.0.87) – 0.85 (95%CI:0.78-
281 0.93), and was 0.73 (0.67-0.79) for a high level of physical activity (reference low level of physical
282 activity)^{43,99–101}. For dementia incidence, effect sizes for a moderate level of physical activity ranged
283 from 0.76 (95%CI:0.61-0.94) – 0.80 (95%CI:0.67-0.94), and from 0.63 (95%CI:0.45-0.89) – 0.80
284 (95%CI:0.77-0.84) for a high level of physical activity^{51,101–106}. No meta-analyses were found that
285 assessed the relationship physical activity and LLD incidence.

286

287 *Purpose in life*

288 Three meta-analyses described purpose in life as a risk factor for dementia¹⁰⁷⁻¹⁰⁹, with effect sizes
289 ranging from 0.76 (95%CI:0.72-0.79) – 0.81 (95%CI:0.78-0.85) (reference no purpose in life)¹⁰⁷⁻¹⁰⁹.
290 No meta-analyses were found that assessed the relationship purpose in life and stroke or LLD
291 incidence.

292

293 *Sleep*

294 Fourteen meta-analyses described sleep as a risk factor. For stroke incidence, the effect sizes of short
295 sleep (≤ 6 hours) ranged from 1.00 (95%CI:0.97-1.24) – 1.71(95%CI:1.39-2.02), for long sleep (≥ 8
296 hours) it ranged from 1.12 (95%CI:1.01-1.24) – 2.12 (95%CI:1.51-2.73), and for insomnia the effect
297 size was 1.55 (95%CI:1.39-1.72) (reference 6-8 hours of sleep)^{36,110-117}. For dementia incidence, the
298 effect size for long sleep was 1.77 (95%CI:1.32-2.37), for short sleep 1.20 (95%CI:0.91-1.59), for
299 insomnia it ranged 1.17 (95%CI 0.95-1.43) – 1.53 (95%CI:1.07-2.18), and for sleep disturbance, it
300 was 1.19 (95%CI1.11-1.29)¹¹⁸⁻¹²⁰. For LLD, the effect sizes for sleep disturbance ranged from 1.2
301 (95%CI:0.80-1.70) – 1.82 (95%CI:1.69-1.97)^{121,122}.

302

303 *Smoking*

304 Fifteen meta-analyses described smoking as a risk factor. For stroke incidence, the effect sizes ranged
305 from 1.08 (95%CI:1.03-1.13) – 1.30 (95%CI:0.93-1.81) for former smokers, and from 1.31
306 (95%CI:1.20-1.43) – 1.84 (1.72-.198) for current smokers (reference never smoked)^{36,43,47,48,123-126}. For
307 dementia incidence, the effect sizes ranged from 0.99 (95%CI:0.81-1.21) – 1.01 (95%CI:0.96-1.06)
308 for former smokers, and from 1.27 (95%CI:1.02-1.60) – 1.30 (95%CI:1.18-1.45) for current smokers
309 ^{50,51,56,127-129}. For LLD, the effect size for current smoking was 1.35 (95%CI:1.00-1.81)⁷⁴.

310

311 *Social Engagement*

312 Seven meta-analyses described social engagement as a risk factor. For stroke incidence, the effect size
313 for social isolation/loneliness was 1.32 (95%CI:1.04-1.68), and 0.77 (95%CI: 0.57-1.04) for having a
314 larger social network (reference not being lonely / small social network)^{130,131}. For dementia

315 incidence, the effect size for social isolation/loneliness ranged from 1.23 (95%CI:1.16-1.31) – 1.58
316 (95%CI:0.80-3.12), and was 0.81 (95%CI:0.74-0.89) for having a larger social network¹³²⁻¹³⁶. No
317 meta-analyses were found that assessed the relationship social engagement and LLD incidence.

318

319 *Stress*

320 Two meta-analyses described stress as a risk factor. For stroke incidence, the effect size was 1.33
321 (95%CI:1.17-1.50) (reference no perceived stress)¹³⁷. For dementia incidence, the effect size was 1.44
322 (95%CI:1.07-1.95)¹³⁸. No meta-analyses were found that assessed the relationship stress and LLD
323 incidence.

324

325 **Study selection to identify the most relevant effect sizes**

326 Of 182 meta-analyses that met the inclusion criteria, 59 were selected to calculate DALY-weighted
327 risk factors for a composite outcome. An overview of the selected studies is presented in Table 1, with
328 the reasoning for selection detailed in Table S5. Study characteristics are reported in Table S6.

329

330 **DALY weighted risk factors for a composite outcome**

331 The calculated DALY weighted effect sizes for each risk factors are presented in Table 2 and Figure
332 3 (intermediate calculations Table S7). Highest risk of age-related brain disease were found in
333 hypertension, with a normalized beta of 87 and severe kidney disease (eGFR<30 ml/min/1.73m²),
334 with a normalized beta of 60. The highest protective effect sizes were found in leisure time cognitive
335 activity, with a normalized beta of -54 and high levels of physical activity with a normalized beta of -
336 34 (Figure 4).

337

Discussion

338

339 This study identified 18 overlapping modifiable risk factors for stroke, dementia, and LLD and
340 calculated their relative impacts on a composite outcome using DALY-weighted beta-coefficients. By
341 analyzing data from two systematic reviews, we weighted these risk factors according to their
342 contribution to the burden of age-related brain diseases. This approach provided a comprehensive
343 understanding of the relative impacts of each risk factor on the risk of a composite outcome of age-
344 related brain disease.

345

346 When assessing individual components, hypertension was the factor with the highest individual
347 weight. This is mainly attributable to the well-established significant association between stroke and
348 hypertension^{3,139}, and is reinforced by our methods' DALY-based weighting system, which assigns
349 greater impact to stroke compared to dementia or LLD¹⁴⁰. Cholesterol showed limited weight with no
350 significant LDL effect. We focused on all strokes, not distinguishing between ischemic and
351 hemorrhagic types, which might have attenuated the effect due to the contradicting impact of
352 cholesterol levels across stroke subtypes¹⁴¹. Additionally, excluding meta-analysis on specific
353 treatments or dose-responses limited available cholesterol studies. We also revealed substantial
354 weights of leisure time cognitive activities, purpose in life, and absence of social isolation. These
355 weights are mainly due to their association with dementia, where reverse causality may play a
356 significant role¹⁴². Further, long sleep duration emerged as a major risk factor, potentially due to its
357 relationship with possible confounders such as obesity, hypertension, and diabetes or due to reverse
358 causality or confounding by aging. We focused on individual dietary elements as outlined by AHA
359 Life's Essential 8 and the DASH diet. While we did not explore the complex interplay between these
360 dietary components^{118,143,144}, there could be an overestimation of the weights of diet if combined in a
361 future tool that builds on the results of our analysis¹⁴⁵. Furthermore, dietary comparisons were often
362 made between the highest and lowest quartiles, limiting the clinical applicability. Pain showed a
363 significant effect on dementia risk, likely due to the direct effects of pain and the associated reduction
364 in physical activity⁹⁸, as well as possible reverse causality¹⁴⁶. Finally, depression was included in our

365 analysis not only as an outcome but also as a risk factor due to its bidirectional associations with
366 vascular brain disease¹⁴⁷. Depressive symptoms showed an increased risk of stroke, which might be
367 due to both immunological and inflammation effects¹⁴⁸, as well as its association with poor health
368 behaviors such as smoking and physical inactivity¹⁴⁹. As we did not include disease-specific
369 populations, we did not assess the associations of post-stroke and post-dementia depression^{150,151}.

370

371 Some limitations should be considered when interpreting our results. First, we only included
372 overlapping risk factors across the three age-related brain diseases, thereby possibly excluding
373 important modifiable risk factors for an individual disease, such as personality attributes and
374 maladaptive thoughts and behaviors for LLD¹⁵². However, emerging evidence shows similarities in
375 the biological pathology of dementia, stroke, and LLD, particularly due to small vessel disease -
376 which subsequently has overlapping modifiable risk factors^{3,9,153}. Second, potential interactions
377 between risk factors, such as interactions or collinearity, were not considered^{143,154}. Third, variations
378 in definitions across different meta-analyses were encountered during our weighted risk factor
379 calculations, which limited our use of these categorizations. Fourth, the potential for bias (including
380 reverse causality, particularly important for dementia with its extended prodromal stages) and
381 confounding presents a significant challenge and may have influenced the effect sizes¹⁵⁵. Fifth, we
382 limited inclusion criteria to articles written in English. Finally, the limited amount of published meta-
383 analyses on LLD risk factors could affect our risk factor weight calculations' overall
384 comprehensiveness, and representativeness.

385

386 Given the limited meta-analyses on modifiable risk factors for LLD, future research should prioritize
387 producing high-quality meta-analyses in this area. The overlap in modifiable risk factors presents an
388 opportunity to simultaneously reduce the risk of stroke, dementia, and LLD. Developing holistic tools
389 or models that effectively address these factors could facilitate the prevention and management of
390 age-related brain diseases^{10,24,25}. This study provided insights into the relative impact of modifiable
391 risk factors, filling a critical gap in the literature necessary for building such comprehensive tools or
392 models. Future research can use our findings as an empirical foundation for building such tools.

393 Future studies should explore certain areas that our current calculations have not fully resolved, to
394 enhance the development of a tool or model ready for validation. These areas include assessing the
395 utility and feasibility of the findings, which should incorporate an evaluation of social determinants of
396 health, as well as refining the calibration process. These shortcomings could be addressed in a Delphi
397 process¹⁵⁶, ensuring the development of a comprehensive tool that leverages all available evidence to
398 empower, educate, and motivate patients and practitioners to adopt lifestyle changes and reduce the
399 risk of stroke, dementia, and LLD¹³.

400

401 **Conclusion**

402 In this study, we systematically identified overlapping modifiable risk factors and calculated the
403 relative impact of these factors on the risk of a composite outcome of stroke, dementia, and
404 depression. These findings could guide preventative strategies and could serve as an empirical
405 foundation for future development of tools that can empower people to change modifiable risk factors
406 associated with these diseases.

Disclosures

C.D.A. receives sponsored research support from the US National Institutes of Health, the American Heart Association, and Bayer AG, and has consulted for ApoPharma. M.C. is supported by the Wellcome Trust [grant number 205339/Z/16/Z]. JR receives sponsored research support from the US National Institutes of Health and the American Heart Association, receives payments for consulting and expert testimony from the National Football League, consulting for Eli Lilly, and has a leadership or fiduciary role at Columbia University and Lancet Neurology. G.F. receives sponsored research support from the National Institute of Mental Health Clinical Global Mental Health Research T32 Fellowship, receives royalties or licenses from Johns Hopkins University Press, University of Chicago Press, Belvoir Press, and the American Psychiatric Press, is on a Data Safety Monitoring Board or Advisory Board of Healthy Hearts Healthy Minds DSMB, is a Board of Directors member at the Rosalynn Carter Institute, and has stock or stock options from Revival Therapeutics Consultant.

Data sharing statement

This manuscript only utilized previously published data. All data employed in this study, including the intermediate calculations, are comprehensively presented in the supplementary tables accompanying this manuscript. Should there be any inquiries or requests for further clarification regarding the data, please contact the corresponding author.

Acknowledgment

Funding: US National Institutes of Health and American Heart Association.

References

1. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X
2. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019). *Seattle, United States: Institute for Health Metrics and Evaluation (IHME)*. Published online 2020.
3. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0
4. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation.* 2022;145(8):e153-e639. doi:10.1161/CIR.0000000000001052
5. Zenebe Y, Akele B, W/Selassie M, Necho M. Prevalence and determinants of depression among old age: a systematic review and meta-analysis. *Ann Gen Psychiatry.* 2021;20(1):55. doi:10.1186/s12991-021-00375-x
6. Chang SC, Pan A, Kawachi I, Okereke OI. Risk factors for late-life depression: A prospective cohort study among older women. *Prev Med.* 2016;91:144-151. doi:10.1016/j.ypmed.2016.08.014
7. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0
8. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry.* 2022;9(2):137-150. doi:10.1016/S2215-0366(21)00395-3
9. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet.* 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
10. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. *Circulation.* 2022;146(5):e18-e43. doi:10.1161/CIR.0000000000001078
11. Empana JP, Boutouyrie P, Lemogne C, Jouven X, van Sloten TT. Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives. *Biological Psychiatry.* 2021;90(4):214-225. doi:10.1016/j.biopsych.2021.04.012
12. Cannistraro RJ, Badi M, Eidelman BH, Dickson DW, Middlebrooks EH, Meschia JF. CNS small vessel disease: A clinical review. *Neurology.* 2019;92(24):1146-1156. doi:10.1212/WNL.0000000000007654

13. Singh SD, Gutierrez-Martinez L, Newhouse A, Sonni A, Chemali Z, Rosand J. Brain health begins with brain care. *Lancet Neurol.* 2022;21(11):961-962. doi:10.1016/S1474-4422(22)00397-0
14. Schiepers OJG, Köhler S, Deckers K, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. *Int J Geriatr Psychiatry.* 2018;33(1):167-175. doi:10.1002/gps.4700
15. Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. *Prev Sci.* 2013;14(4):411-421. doi:10.1007/s11121-012-0313-2
16. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. *Stroke.* 1994;25(1):40-43. doi:10.1161/01.str.25.1.40
17. Cattelani L, Murri MB, Chesani F, Chiari L, Bandinelli S, Palumbo P. Risk Prediction Model for Late Life Depression: Development and Validation on Three Large European Datasets. *IEEE J Biomed Health Inform.* 2019;23(5):2196-2204. doi:10.1109/JBHI.2018.2884079
18. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. *BMJ.* 2013;346:f2573. doi:10.1136/bmj.f2573
19. Xing X, Yang X, Liu F, et al. Predicting 10-Year and Lifetime Stroke Risk in Chinese Population. *Stroke.* 2019;50(9):2371-2378. doi:10.1161/STROKEAHA.119.025553
20. Qiao Q, Gao W, Laatikainen T, Vartiainen E. Layperson-oriented vs. clinical-based models for prediction of incidence of ischemic stroke: National FINRISK Study. *Int J Stroke.* 2012;7(8):662-668. doi:10.1111/j.1747-4949.2011.00692.x
21. Fisher S, Hsu A, Mojaverian N, et al. Dementia Population Risk Tool (DemPoRT): study protocol for a predictive algorithm assessing dementia risk in the community. *BMJ Open.* 2017;7(10):e018018. doi:10.1136/bmjopen-2017-018018
22. Barnes DE, Beiser AS, Lee A, et al. Development and validation of a brief dementia screening indicator for primary care. *Alzheimers Dement.* 2014;10(6):656-665.e1. doi:10.1016/j.jalz.2013.11.006
23. Huque MH, Kootar S, Eramudugolla R, et al. CogDrisk, ANU-ADRI, CAIDE, and LIBRA Risk Scores for Estimating Dementia Risk. *JAMA Netw Open.* 2023;6(8):e2331460. doi:10.1001/jamanetworkopen.2023.31460
24. Rost NS, Salinas J, Jordan JT, et al. The Brain Health Imperative in the 21st Century—A Call to Action. *Neurology.* 2023;101(13):570-579. doi:10.1212/WNL.0000000000207739

25. Lazar RM, Howard VJ, Kernan WN, et al. A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association. *Stroke*. 2021;52(6):e295-e308. doi:10.1161/STR.0000000000000367
26. *The Joanna Briggs Institute (2014) Joanna Briggs Institute Reviewers' Manual. 2014 Edition, The Joanna Briggs Institute. [Http://Joannabriggs.Org/Assets/Docs/Sumari/ReviewersManual-The-Systematic-Review-of-Economic-Evaluation-Evidence-2014_v2.Pdf](http://Joannabriggs.Org/Assets/Docs/Sumari/ReviewersManual-The-Systematic-Review-of-Economic-Evaluation-Evidence-2014_v2.Pdf).*
27. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
28. Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. *BMC Med Res Methodol*. 2018;18(1):5. doi:10.1186/s12874-017-0468-4
29. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010;21(1):128-138. doi:10.1097/EDE.0b013e3181c30fb2
30. Rudin C. Stop Explaining Black Box Machine Learning Models for High Stakes Decisions and Use Interpretable Models Instead. *Nat Mach Intell*. 2019;1(5):206-215. doi:10.1038/s42256-019-0048-x
31. *Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia. Available at [Www.Covidence.Org](http://www.Covidence.Org).*
32. Haidich AB. Meta-analysis in medical research. *Hippokratia*. 2010;14(Suppl 1):29-37.
33. Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices for quantitative bias analysis. *Int J Epidemiol*. 2014;43(6):1969-1985. doi:10.1093/ije/dyu149
34. Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Adv Nutr*. 2020;11(5):1150-1160. doi:10.1093/advances/nmaa041
35. Shor E, Roelfs D, Vang ZM. The "Hispanic mortality paradox" revisited: Meta-analysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality. *Social Science & Medicine*. 2017;186:20-33. doi:10.1016/j.socscimed.2017.05.049
36. Yuan W, Wu B, Lou M, et al. Identification of Risk Factors for Stroke in China: A Meta-Analysis of Prospective Cohort Studies. *Frontiers in Neurology*. 2022;13 doi:10.3389/fneur.2022.847304
37. Zheng YL, Lian F, Shi Q, et al. Alcohol intake and associated risk of major cardiovascular outcomes in women compared with men: a systematic review

- and meta-analysis of prospective observational studies. *BMC Public Health*. 2015;15:773. doi:10.1186/s12889-015-2081-y
38. Zhang X, Shu L, Si C, et al. Dietary Patterns and Risk of Stroke in Adults: A Systematic Review and Meta-analysis of Prospective Cohort Studies. *J Stroke Cerebrovasc Dis*. 2015;24(10):2173-2182. doi:10.1016/j.jstrokecerebrovasdis.2015.05.035
 39. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. *BMJ*. 2011;342:d671. doi:10.1136/bmj.d671
 40. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. *JAMA*. 2003;289(5):579-588. doi:10.1001/jama.289.5.579
 41. Xu W, Wang H, Wan Y, et al. Alcohol consumption and dementia risk: a dose-response meta-analysis of prospective studies. *Eur J Epidemiol*. 2017;32(1):31-42. doi:10.1007/s10654-017-0225-3
 42. Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. *Am J Geriatr Psychiatry*. 2009;17(7):542-555. doi:10.1097/JGP.0b013e3181a2fd07
 43. Wang J, Wen X, Li W, Li X, Wang Y, Lu W. Risk Factors for Stroke in the Chinese Population: A Systematic Review and Meta-Analysis. *J Stroke Cerebrovasc Dis*. 2017;26(3):509-517. doi:10.1016/j.jstrokecerebrovasdis.2016.12.002
 44. Lee M, Saver JL, Chang B, Chang KH, Hao Q, Ovbiagele B. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. *Neurology*. 2011;77(14):1330-1337. doi:10.1212/WNL.0b013e3182315234
 45. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. *Neurology*. 2014;82(13):1153-1161. doi:10.1212/WNL.0000000000000268
 46. Han M, Li Q, Liu L, et al. Prehypertension and risk of cardiovascular diseases: A meta-Analysis of 47 cohort studies. *Journal of Hypertension*. 2019;37(12):2325-2332. doi:10.1097/HJH.0000000000002191
 47. Birhanu MM, Zaman SB, Thrift AG, Evans RG, Zengin A. Risk factors for incident cardiovascular events among adults in low- and middle-income countries: A systematic review and meta-analysis of prospective cohort studies. *Prev Med*. 2022;158:107036. doi:10.1016/j.ypmed.2022.107036
 48. Wu Y, Xiong Y, Wang P, et al. Risk factors of cardiovascular and cerebrovascular diseases in young and middle-aged adults: A meta-analysis. *Medicine (Baltimore)*. 2022;101(48):e32082. doi:10.1097/MD.00000000000032082

49. Ou YN, Tan CC, Shen XN, et al. Blood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209 Prospective Studies. *Hypertension*. 2020;76(1):217-225. doi:10.1161/HYPERTENSIONAHA.120.14993
50. Li XY, Zhang M, Xu W, et al. Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies. *Curr Alzheimer Res*. 2019;16(14):1254-1268. doi:10.2174/1567205017666200103111253
51. Wu J, Xiong Y, Xia X, et al. Can dementia risk be reduced by following the American Heart Association's Life's Simple 7? A systematic review and dose-response meta-analysis. *Ageing Res Rev*. 2023;83:101788. doi:10.1016/j.arr.2022.101788
52. Lennon MJ, Lam BCP, Lipnicki DM, et al. Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life: An Individual Participant Data Meta-Analysis. *JAMA Netw Open*. 2023;6(9):e2333353. doi:10.1001/jamanetworkopen.2023.33353
53. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. *Stroke*. 2010;41(5):e418-26. doi:10.1161/STROKEAHA.109.576967
54. Riaz H, Khan MS, Siddiqi TJ, et al. Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. *JAMA Netw Open*. 2018;1(7):e183788. doi:10.1001/jamanetworkopen.2018.3788
55. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. *Obes Rev*. 2011;12(5):e426-37. doi:10.1111/j.1467-789X.2010.00825.x
56. Ford E, Greenslade N, Paudyal P, et al. Predicting dementia from primary care records: A systematic review and meta-analysis. *PLoS One*. 2018;13(3):e0194735. doi:10.1371/journal.pone.0194735
57. Qu Y, Hu HY, Ou YN, et al. Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies. *Neurosci Biobehav Rev*. 2020;115:189-198. doi:10.1016/j.neubiorev.2020.05.012
58. Pedditzi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. *Age Ageing*. 2016;45(1):14-21. doi:10.1093/ageing/afv151
59. Loef M, Walach H. Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. *Obesity (Silver Spring)*. 2013;21(1):E51-5. doi:10.1002/oby.20037

60. Danat IM, Clifford A, Partridge M, et al. Impacts of Overweight and Obesity in Older Age on the Risk of Dementia: A Systematic Literature Review and a Meta-Analysis. *J Alzheimers Dis.* 2019;70(s1):S87-S99. doi:10.3233/JAD-180763
61. Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. *Obes Rev.* 2008;9(3):204-218. doi:10.1111/j.1467-789X.2008.00473.x
62. Rahmani J, Roudsari AH, Bawadi H, et al. Body mass index and risk of Parkinson, Alzheimer, Dementia, and Dementia mortality: a systematic review and dose-response meta-analysis of cohort studies among 5 million participants. *Nutr Neurosci.* 2022;25(3):423-431. doi:10.1080/1028415X.2020.1758888
63. Shi H, Ge Y, Wang H, Zhang Y, Teng W, Tian L. Fasting blood glucose and risk of Stroke: A Dose-Response meta-analysis. *Clin Nutr.* 2021;40(5):3296-3304. doi:10.1016/j.clnu.2020.10.054
64. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of pre-diabetes on future risk of stroke: meta-analysis. *BMJ.* 2012;344:e3564. doi:10.1136/bmj.e3564
65. Liao HW, Saver J, Yeh HC, et al. Low fasting glucose and future risks of major adverse outcomes in people without baseline diabetes or cardiovascular disease: a systematic review and meta-analysis. *BMJ Open.* 2019;9(7):e026010. doi:10.1136/bmjopen-2018-026010
66. Xue M, Xu W, Ou YN, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. *Ageing Res Rev.* 2019;55:100944. doi:10.1016/j.arr.2019.100944
67. Banach M, Shekoohi N, Mikhailidis DP, Lip GYH, Hernandez AV, Mazidi M. Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988). *Archives of Medical Science.* 2022;18(4):912-929. doi:10.5114/aoms/145970
68. Qie R, Liu L, Zhang D, et al. Dose-Response Association Between High-Density Lipoprotein Cholesterol and Stroke: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *Prev Chronic Dis.* 2021;18:E45. doi:10.5888/pcd18.200278
69. Peters SA, Singhatheh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. *Atherosclerosis.* 2016;248:123-131. doi:10.1016/j.atherosclerosis.2016.03.016
70. Liu Y, Jin X, Fu K, et al. Non-traditional lipid profiles and the risk of stroke: A systematic review and meta-analysis. *Nutr Metab Cardiovasc Dis.* 2023;33(4):698-714. doi:10.1016/j.numecd.2023.01.003

71. Wang P, Sun J, Xie T, Lv S. Serum non-high-density lipoprotein cholesterol and risk of stroke in the general population: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2018;11(3):1467-1474.
72. Zhu Y, Liu X, Zhu R, Zhao J, Wang Q. Lipid levels and the risk of dementia: A dose-response meta-analysis of prospective cohort studies. *Ann Clin Transl Neurol*. 2022;9(3):296-311. doi:10.1002/acn3.51516
73. Anstey KJ, Ashby-Mitchell K, Peters R. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis. *J Alzheimers Dis*. 2017;56(1):215-228. doi:10.3233/JAD-160826
74. Valkanova V, Ebmeier KP. Vascular risk factors and depression in later life: a systematic review and meta-analysis. *Biol Psychiatry*. 2013;73(5):406-413. doi:10.1016/j.biopsych.2012.10.028
75. Yates LA, Ziser S, Spector A, Orrell M. Cognitive leisure activities and future risk of cognitive impairment and dementia: systematic review and meta-analysis. *Int Psychogeriatr*. 2016;28(11):1791-1806. doi:10.1017/S1041610216001137
76. Eurelings LSM, van Dalen JW, Ter Riet G, et al. Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: A systematic review and meta-analysis of individual participant data. *Clinical Epidemiology*. 2018;10. doi:10.2147/CLEP.S150915
77. Hu D, Huang J, Wang Y, Zhang D, Qu Y. Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies. *Stroke*. 2014;45(6):1613-1619. doi:10.1161/STROKEAHA.114.004836
78. Bechthold A, Boeing H, Schwedhelm C, et al. Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies. *Crit Rev Food Sci Nutr*. 2019;59(7):1071-1090. doi:10.1080/10408398.2017.1392288
79. Hu H, Zhao Y, Feng Y, et al. Consumption of whole grains and refined grains and associated risk of cardiovascular disease events and all-cause mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. *Am J Clin Nutr*. 2023;117(1):149-159. doi:10.1016/j.ajcnut.2022.10.010
80. Papp RE, Hasenegger V, Ekmekcioglu C, Schwingshackl L. Association of poultry consumption with cardiovascular diseases and all-cause mortality: a systematic review and dose response meta-analysis of prospective cohort studies. *Crit Rev Food Sci Nutr*. 2023;63(15):2366-2387. doi:10.1080/10408398.2021.1975092
81. Mendes V, Niforou A, Kasdagli MI, Ververis E, Naska A. Intake of legumes and cardiovascular disease: A systematic review and dose-response meta-analysis. *Nutr Metab Cardiovasc Dis*. 2023;33(1):22-37. doi:10.1016/j.numecd.2022.10.006

82. Shao C, Tang H, Zhao W, He J. Nut intake and stroke risk: A dose-response meta-analysis of prospective cohort studies. *Sci Rep.* 2016;6:30394. doi:10.1038/srep30394
83. Wang Y, Zhao R, Wang B, Zhao C, Zhu B, Tian X. The Dose-Response Associations of Sugar-Sweetened Beverage Intake with the Risk of Stroke, Depression, Cancer, and Cause-Specific Mortality: A Systematic Review and Meta-Analysis of Prospective Studies. *Nutrients.* 2022;14(4). doi:10.3390/nu14040777
84. Rossi M, Turati F, Lagiou P, Trichopoulos D, La Vecchia C, Trichopoulou A. Relation of dietary glycemic load with ischemic and hemorrhagic stroke: a cohort study in Greece and a meta-analysis. *Eur J Nutr.* 2015;54(2):215-222. doi:10.1007/s00394-014-0702-3
85. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ.* 2009;339:b4567. doi:10.1136/bmj.b4567
86. Kang ZQ, Yang Y, Xiao B. Dietary saturated fat intake and risk of stroke: Systematic review and dose-response meta-analysis of prospective cohort studies. *Nutr Metab Cardiovasc Dis.* 2020;30(2):179-189. doi:10.1016/j.numecd.2019.09.028
87. Zhang XW, Yang Z, Li M, Li K, Deng YQ, Tang ZY. Association between dietary protein intake and risk of stroke: A meta-analysis of prospective studies. *Int J Cardiol.* 2016;223:548-551. doi:10.1016/j.ijcard.2016.08.106
88. Talebi S, Asoudeh F, Naeini F, Sadeghi E, Travica N, Mohammadi H. Association between animal protein sources and risk of neurodegenerative diseases: a systematic review and dose-response meta-analysis. *Nutr Rev.* 2023;81(9):1131-1143. doi:10.1093/nutrit/nuac114
89. Bakre AT, Chen R, Khutan R, et al. Association between fish consumption and risk of dementia: a new study from China and a systematic literature review and meta-analysis. *Public Health Nutr.* 2018;21(10):1921-1932. doi:10.1017/S136898001800037X
90. Zhu RZ, Chen MQ, Zhang ZW, Wu TY, Zhao WH. Dietary fatty acids and risk for Alzheimer's disease, dementia, and mild cognitive impairment: A prospective cohort meta-analysis. *Nutrition.* 2021;90:111355. doi:10.1016/j.nut.2021.111355
91. Sun Q, Yang Y, Wang X, Yang R, Li X. The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis. *Journal of Prevention of Alzheimer's Disease.* 2022;9(2):323-330. doi:10.14283/jpad.2021.71
92. Khosravipour M, Rajati F. Sensorineural hearing loss and risk of stroke: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):11021. doi:10.1038/s41598-021-89695-2

93. Liang Z, Li A, Xu Y, Qian X, Gao X. Hearing Loss and Dementia: A Meta-Analysis of Prospective Cohort Studies. *Frontiers in Aging Neuroscience*. 2021;13. doi:10.3389/fnagi.2021.695117
94. Lawrence BJ, Jayakody DMP, Bennett RJ, Eikelboom RH, Gasson N, Friedland PL. Hearing Loss and Depression in Older Adults: A Systematic Review and Meta-analysis. *Gerontologist*. 2020;60(3):e137-e154. doi:10.1093/geront/gnz009
95. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. *BMJ*. 2010;341:c4249. doi:10.1136/bmj.c4249
96. Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. *Nephrol Dial Transplant*. 2015;30(7):1162-1169. doi:10.1093/ndt/gfv009
97. Kjaergaard AD, Ellervik C, Witte DR, Nordestgaard BG, Frikke-Schmidt R, Bojesen SE. Kidney function and risk of dementia: Observational study, meta-analysis, and two-sample mendelian randomization study. *Eur J Epidemiol*. 2022;37(12):1273-1284. doi:10.1007/s10654-022-00923-z
98. Yuan H, Ahmed WL, Liu M, Tu S, Zhou F, Wang S. Contribution of pain to subsequent cognitive decline or dementia: A systematic review and meta-analysis of cohort studies. *Int J Nurs Stud*. 2023;138:104409. doi:10.1016/j.ijnurstu.2022.104409
99. Wendel-Vos GC, Schuit AJ, Feskens EJ, et al. Physical activity and stroke. A meta-analysis of observational data. *Int J Epidemiol*. 2004;33(4):787-798. doi:10.1093/ije/dyh168
100. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. *Stroke*. 2003;34(10):2475-2481. doi:10.1161/01.STR.0000091843.02517.9D
101. Kivimäki M, Singh-Manoux A, Pentti J, et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. *BMJ*. 2019;365:l1495. doi:10.1136/bmj.l1495
102. Xu W, Wang HF, Wan Y, Tan CC, Yu JT, Tan L. Leisure time physical activity and dementia risk: a dose-response meta-analysis of prospective studies. *BMJ Open*. 2017;7(10):e014706. doi:10.1136/bmjopen-2016-014706
103. Iso-Markku P, Kujala UM, Knittle K, Polet J, Vuoksima E, Waller K. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. *Br J Sports Med*. 2022;56(12):701-709. doi:10.1136/bjsports-2021-104981
104. de Souto Barreto P, Demougeot L, Vellas B, Rolland Y. Exercise Training for Preventing Dementia, Mild Cognitive Impairment, and Clinically Meaningful Cognitive Decline: A Systematic Review and Meta-analysis. *J Gerontol A Biol Sci Med Sci*. 2018;73(11):1504-1511. doi:10.1093/gerona/glx234

105. Lee J. The Relationship Between Physical Activity and Dementia: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *J Gerontol Nurs.* 2018;44(10):22-29. doi:10.3928/00989134-20180814-01
106. Guure CB, Ibrahim NA, Adam MB, Said SM. Impact of Physical Activity on Cognitive Decline, Dementia, and Its Subtypes: Meta-Analysis of Prospective Studies. *Biomed Res Int.* 2017;2017:9016924. doi:10.1155/2017/9016924
107. Sutin DAR, Luchetti M, Aschwanden D, Stephan Y, Sesker AA, Terracciano A. Sense of meaning and purpose in life and risk of incident dementia: New data and meta-analysis. *Arch Gerontol Geriatr.* 2023;105:104847. doi:10.1016/j.archger.2022.104847
108. Bell G, Singham T, Saunders R, John A, Stott J. Positive psychological constructs and association with reduced risk of mild cognitive impairment and dementia in older adults: A systematic review and meta-analysis. *Ageing Res Rev.* 2022;77:101594. doi:10.1016/j.arr.2022.101594
109. Sutin AR, Aschwanden D, Luchetti M, Stephan Y, Terracciano A. Sense of Purpose in Life Is Associated with Lower Risk of Incident Dementia: A Meta-Analysis. *J Alzheimers Dis.* 2021;83(1):249-258. doi:10.3233/JAD-210364
110. Wu TT, Zou YL, Xu KD, et al. Insomnia and multiple health outcomes: umbrella review of meta-analyses of prospective cohort studies. *Public Health.* 2023;215. doi:10.1016/j.puhe.2022.11.021
111. Wang H, Sun J, Sun M, Liu N, Wang M. Relationship of sleep duration with the risk of stroke incidence and stroke mortality: an updated systematic review and dose-response meta-analysis of prospective cohort studies. *Sleep Med.* 2022;90:267-278. doi:10.1016/j.sleep.2021.11.001
112. Li W, Wang D, Cao S, et al. Sleep duration and risk of stroke events and stroke mortality: A systematic review and meta-analysis of prospective cohort studies. *Int J Cardiol.* 2016;223:870-876. doi:10.1016/j.ijcard.2016.08.302
113. Leng Y, Cappuccio FP, Wainwright NW, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. *Neurology.* 2015;84(11):1072-1079. doi:10.1212/WNL.0000000000001371
114. Jike M, Itani O, Watanabe N, Buysse DJ, Kaneita Y. Long sleep duration and health outcomes: A systematic review, meta-analysis and meta-regression. *Sleep Med Rev.* 2018;39:25-36. doi:10.1016/j.smrv.2017.06.011
115. He Q, Sun H, Wu X, et al. Sleep duration and risk of stroke: a dose-response meta-analysis of prospective cohort studies. *Sleep Med.* 2017;32:66-74. doi:10.1016/j.sleep.2016.12.012
116. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J.* 2011;32(12):1484-1492. doi:10.1093/eurheartj/ehr007

117. Ge B, Guo X. Short and long sleep durations are both associated with increased risk of stroke: a meta-analysis of observational studies. *Int J Stroke*. 2015;10(2):177-184. doi:10.1111/ijvs.12398
118. Fan L, Xu W, Cai Y, Hu Y, Wu C. Sleep Duration and the Risk of Dementia: A Systematic Review and Meta-analysis of Prospective Cohort Studies. *J Am Med Dir Assoc*. 2019;20(12):1480-1487.e5. doi:10.1016/j.jamda.2019.06.009
119. de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. *J Psychiatr Res*. 2016;77:109-115. doi:10.1016/j.jpsychires.2016.02.021
120. Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. *Sleep Med Rev*. 2018;40:4-16. doi:10.1016/j.smr.2017.06.010
121. Bao YP, Han Y, Ma J, et al. Cooccurrence and bidirectional prediction of sleep disturbances and depression in older adults: Meta-analysis and systematic review. *Neurosci Biobehav Rev*. 2017;75:257-273. doi:10.1016/j.neubiorev.2017.01.032
122. Hill Almeida LM, Flicker L, Hankey GJ, Golledge J, Yeap BB, Almeida OP. Disrupted sleep and risk of depression in later life: A prospective cohort study with extended follow up and a systematic review and meta-analysis. *Journal of Affective Disorders*. 2022;309. doi:10.1016/j.jad.2022.04.133
123. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *British Medical Journal*. 1989;298(6676):789-794. doi:10.1136/bmj.298.6676.789
124. Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. *Stroke*. 2013;44(10):2821-2828. doi:10.1161/STROKEAHA.113.002342
125. Pan B, Jin X, Jun L, Qiu S, Zheng Q, Pan M. The relationship between smoking and stroke: A meta-analysis. *Medicine (Baltimore)*. 2019;98(12):e14872. doi:10.1097/MD.00000000000014872
126. Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. *BMJ*. 2015;350:h1551. doi:10.1136/bmj.h1551
127. Cao L, Tan L, Wang HF, et al. Dietary Patterns and Risk of Dementia: a Systematic Review and Meta-Analysis of Cohort Studies. *Mol Neurobiol*. 2016;53(9):6144-6154. doi:10.1007/s12035-015-9516-4
128. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. *PLoS One*. 2015;10(3):e0118333. doi:10.1371/journal.pone.0118333

129. Anstey KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. *Am J Epidemiol.* 2007;166(4):367-378. doi:10.1093/aje/kwm116
130. Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation as risk factors for coronary heart disease and stroke: Systematic review and meta-analysis of longitudinal observational studies. *Heart.* 2016;102(13):1009-1016. doi:10.1136/heartjnl-2015-308790
131. Park JW, Mealy R, Saldanha IJ, et al. Multilevel resilience resources and cardiovascular disease in the United States: A systematic review and meta-analysis. *Health Psychology.* 2022;41(4):278-290. doi:10.1037/hea0001069
132. Sommerlad A, Rieger J, Singh-Manoux A, Lewis G, Livingston G. Marriage and risk of dementia: systematic review and meta-analysis of observational studies. *J Neurol Neurosurg Psychiatry.* 2018;89(3):231-238. doi:10.1136/jnnp-2017-316274
133. Qiao L, Wang G, Tang Z, et al. Association between loneliness and dementia risk: A systematic review and meta-analysis of cohort studies. *Frontiers in Human Neuroscience.* 2022;16. doi:10.3389/fnhum.2022.899814
134. Kuiper JS, Zuidersma M, Oude Voshaar RC, et al. Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. *Ageing Res Rev.* 2015;22:39-57. doi:10.1016/j.arr.2015.04.006
135. Desai R, John A, Stott J, Charlesworth G. Living alone and risk of dementia: A systematic review and meta-analysis. *Ageing Res Rev.* 2020;62:101122. doi:10.1016/j.arr.2020.101122
136. Wang S, Molassiotis A, Guo C, Leung ISH, Leung AYM. Association between social integration and risk of dementia: A systematic review and meta-analysis of longitudinal studies. *J Am Geriatr Soc.* 2023;71(2):632-645. doi:10.1111/jgs.18094
137. Booth J, Connelly L, Lawrence M, et al. Evidence of perceived psychosocial stress as a risk factor for stroke in adults: A meta-analysis. *BMC Neurology.* 2015;15(1). doi:10.1186/s12883-015-0456-4
138. Franks KH, Bransby L, Saling MM, Pase MP. Association of Stress with Risk of Dementia and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. *J Alzheimers Dis.* 2021;82(4):1573-1590. doi:10.3233/JAD-210094
139. O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet.* 2016;388(10046):761-775. doi:10.1016/S0140-6736(16)30506-2
140. Seattle, United States: Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019). Global Burden of Disease Collaborative Network.

141. Hackam DG, Hegele RA. Cholesterol Lowering and Prevention of Stroke. *Stroke*. 2019;50(2):537-541. doi:10.1161/STROKEAHA.118.023167
142. Floud S, Balkwill A, Reeves GK, Peto R, Beral V. Cognitive and social activities and long-term dementia risk – Authors’ reply. *The Lancet Public Health*. 2021;6(5):e270. doi:10.1016/S2468-2667(21)00072-4
143. Mirmiran P, Bahadoran Z, Gaeini Z. Common Limitations and Challenges of Dietary Clinical Trials for Translation into Clinical Practices. *Int J Endocrinol Metab*. 2021;19(3):e108170. doi:10.5812/ijem.108170
144. Buxton OM, Marcelli E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. *Soc Sci Med*. 2010;71(5):1027-1036. doi:10.1016/j.socscimed.2010.05.041
145. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases--incidence: a systematic review and meta-analysis on observational prospective studies. *Nutrition*. 2013;29(4):611-618. doi:10.1016/j.nut.2012.12.018
146. Achterberg W, Lautenbacher S, Husebo B, Erdal A, Herr K. Pain in dementia. *Pain Rep*. 2020;5(1):e803. doi:10.1097/PR9.0000000000000803
147. Thomas AJ, Kalaria RN, O’Brien JT. Depression and vascular disease: what is the relationship? *J Affect Disord*. 2004;79(1-3):81-95. doi:10.1016/S0165-0327(02)00349-X
148. Shimbo D, Chaplin W, Crossman D, Haas D, Davidson KW. Role of depression and inflammation in incident coronary heart disease events. *Am J Cardiol*. 2005;96(7):1016-1021. doi:10.1016/j.amjcard.2005.05.064
149. Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. *Gen Hosp Psychiatry*. 2008;30(2):127-137. doi:10.1016/j.genhosppsych.2007.12.008
150. Wijeratne T, Sales C. Understanding Why Post-Stroke Depression May Be the Norm Rather Than the Exception: The Anatomical and Neuroinflammatory Correlates of Post-Stroke Depression. *J Clin Med*. 2021;10(8). doi:10.3390/jcm10081674
151. Muliayala KP, Varghese M. The complex relationship between depression and dementia. *Ann Indian Acad Neurol*. 2010;13(Suppl 2):S69-73. doi:10.4103/0972-2327.74248
152. Aziz R, Steffens DC. What are the causes of late-life depression? *Psychiatr Clin North Am*. 2013;36(4):497-516. doi:10.1016/j.psc.2013.08.001

153. Farhat NS, Theiss R, Santini T, Ibrahim TS, Aizenstein HJ. Neuroimaging of Small Vessel Disease in Late-Life Depression. *Adv Exp Med Biol*. 2019;1192:95-115. doi:10.1007/978-981-32-9721-0_5
154. Diaz KM, Shimbo D. Physical activity and the prevention of hypertension. *Curr Hypertens Rep*. 2013;15(6):659-668. doi:10.1007/s11906-013-0386-8
155. Sattar N, Preiss D. Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined? *Circulation*. 2017;135(24):2369-2372. doi:10.1161/CIRCULATIONAHA.117.028307
156. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv Nurs*. 2000;32(4):1008-1015.
157. Zhang C, Qin YY, Chen Q, et al. Alcohol intake and risk of stroke: a dose-response meta-analysis of prospective studies. *Int J Cardiol*. 2014;174(3):669-677. doi:10.1016/j.ijcard.2014.04.225
158. Long J, Duan G, Tian W, et al. Hypertension and risk of depression in the elderly: a meta-analysis of prospective cohort studies. *J Hum Hypertens*. 2015;29(8):478-482. doi:10.1038/jhh.2014.112
159. Wang X, Su W, Huang Y, et al. BMI and risk of stroke: a dose-response meta-analysis. *Chinese Journal of Evidence-Based Medicine*. 2022;22(11):1330-1338. doi:10.7507/1672-2531.202205032

Figures and tables

Figure 1: Study Design

	Methodology	Objective
I	Systematic review of risk models	To identify overlapping risk factors for stroke, dementia and late-life depression
II	Systematic review of meta-analysis	To obtain effect sizes of risk factors for each of the three diseases
III	Selection of the most relevant available meta-analysis	To obtain most relevant effect sizes
IV	Calculation of DALY weighted effect sizes	To obtain relative impact of each risk factor on age-related drain disease

Figure 2: Prisma flowchart of the systematic review of meta-analyses.






Figure 3: Effect sizes for stroke, dementia, LLD and a composite outcome.



Abbreviations: BMI: body mass index, dL: deciliter, eGFR: estimated glomerular filtration rate, F: female, FPG: fasting plasma glucose, KG: kilograms, LLD: late-life depression, LDL: low density lipoprotein, M: male, m: meters, mg: milligram, min: minutes, mmHg: millimeters mercury. SSB: sugar sweetened beverages.

Figure 4: Normalized beta-coefficients for a composite outcome



Abbreviations: dL: deciliter, eGFR: estimated glomerular filtration rate, F: female, FPG: fasting plasma glucose, LL: late-life, M: male, m: meters, mg: milligram, ML: midlife min: minutes, mmHg: millimeters mercury.

Tables

Table 1: Selected studies and identification of the most relevant effect size

Risk factor	Stroke					Dementia					Late-life depression				
	Reference	Est.	95% CI	ES	N=	Reference	Est.	95% CI	ES	N=	Reference	Est.	95% CI	ES	N=
Alcohol (ref never)															
≥ 3 standard drinks/day	Zhang ¹⁵⁷	1.20	1.01-1.43	RR	233,689	Xu ⁴¹	1.00	0.39-2.59	RR	73,330	NA	NA	NA	NA	NA
< 3 standard drinks/day	Zhang ¹⁵⁷	1.01	0.93-1.09	RR	414,146	Xu ⁴¹	0.58	0.38-0.90	RR	73,330	NA	NA	NA	NA	NA
1 standard drinks/day	Zhang ¹⁵⁷	0.85	0.75-0.95	RR	414,146	Xu ⁴¹	0.75	0.51-1.11	RR	73,330	NA	NA	NA	NA	NA
Blood pressure (ref <120/80 mmHg)															
140/90 ML	Wang ⁴³	2.68	2.20-3.26	RR	279,088	Ou ⁴⁹	1.20	1.06-1.35	RR	1,320,441	Long ¹⁵⁸	1.16	0.91-1.42	RR	9,647
140/90 LL	Wang ⁴³	2.68	2.20-3.26	RR	279,088	Ou ⁴⁹	1.01	0.96-1.06	RR	57,907	Long ¹⁵⁸	1.16	0.91-1.42	RR	9,647
30-139/ 85-89	Huang ⁴⁵	1.95	1.73-2.21	RR	762,393	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
20-129 / 80-84	Huang ⁴⁵	1.44	1.27-1.63	RR	762,393	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
BMI (ref 18.5-25 kg/m2)															
≥ 30	Wang ¹⁵⁹	1.47	1.02-2.11	RR	4,121,082	Qu ⁵⁷	1.45	1.19-1.78	RR	41,656	NA	NA	NA	NA	NA
25-30	Wang ¹⁵⁹	1.47	1.02-2.11	RR	4,121,082	Qu ⁵⁷	0.78	0.70-0.86	RR	46,472	NA	NA	NA	NA	NA
25-30	Wang ¹⁵⁹	1.25	1.16-1.34	RR	3,458,041	Qu ⁵⁷	1.22	1.07-1.39	RR	53,690	NA	NA	NA	NA	NA
25-30	Wang ¹⁵⁹	1.25	1.16-1.34	RR	3,458,041	Qu ⁵⁷	0.82	0.74-0.92	RR	32,079	NA	NA	NA	NA	NA
< 18.5	Wang ¹⁵⁹	0.93	0.82-1.06	RR	3,917,021	Qu ⁵⁷	1.42	1.12-1.80	RR	33,992	NA	NA	NA	NA	NA
< 18.5	Wang ¹⁵⁹	0.93	0.82-1.06	RR	3,917,021	Qu ⁵⁷	1.23	1.03-1.48	RR	24,556	NA	NA	NA	NA	NA
Blood Sugar (ref fasting plasma glucose < 100 mg/dL)															
> 126	Shi ⁶³	1.79	1.68-1.91	RR	2,524,770	Xue ⁶⁶	1.21	1.06-1.37	RR	2,956,619	NA	NA	NA	NA	NA
100-126	Shi ⁶³	1.16	1.11-1.21	RR	2,537,596	Xue ⁶⁶	1.22	1.06-1.41	RR	2,956,619	NA	NA	NA	NA	NA
Cholesterol (ref TC/LDL low)															
High (Female)	Peters ⁶⁹	0.99	0.87-1.12	RR	786,621	Zhu ⁷²	1.13	1.04-1.22	RR	153,690	Valkanova ⁷⁴	1.08	0.99-1.40	OR	17,959
High (Male)	Peters ⁶⁹	1.14	1.03-1.27	RR	786,621	Zhu ⁷²	1.13	1.04-1.22	RR	153,690	Valkanova ⁷⁴	1.08	0.99-1.40	OR	17,959
DL	Yuan ³⁶	1.09	0.85-1.39	RR	6676	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cognitive activity (ref none)															
Leisure time cognitive activity	NA	NA	NA	NA	NA	Yates ⁷⁵	0.61	0.42-0.90	RR	1,932	NA	NA	NA	NA	NA
Depressive symptoms (ref not present)															
Depressive symptoms	Eurelings ⁷⁶	1.36	1.13-1.51	HR	254,694	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Diet (ref low)															
Vegetables high intake	Hu ⁷⁷	0.86	0.79-0.93	RR	932,545	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Fruit high intake	Bechthold ⁷⁸	0.83	0.77-0.89	RR	45,806	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Whole grain high intake	Hu ⁷⁹	0.93	0.87-1.00	RR	877,897	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Dairy high intake	Bechthold ⁷⁸	0.96	0.90-1.01	RR	452,216	Talebi ⁸⁸	0.72	0.58-0.89	RR	2,757	NA	NA	NA	NA	NA
Fish high intake	Bechthold ⁷⁸	0.95	0.89-1.01	RR	409,128	Bakre ⁸⁹	0.80	0.74-0.87	RR	40,668	NA	NA	NA	NA	NA
poultry high intake	Papp ⁸⁰	0.97	0.87-1.02	RR	1,290,356	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Beans high intake	Mendes ⁸¹	1.00	0.93-1.08	RR	770,735	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Nuts high intake	Shao ⁸²	0.88	0.80-0.97	RR	671,301	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Red meat high intake	Bechthold ⁷⁸	1.16	1.08-1.25	RR	341,767	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sugar Sweetened Beverage	Wang ⁸³	1.12	1.03-1.23	RR	350,684	Sun ⁹¹	2.77	2.23-3.43	HR	5,660	NA	NA	NA	NA	NA
Sweets high intake	Rossi ⁸⁴	1.23	1.07-1.41	RR	350,684	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sodium high intake	Strazzullo ⁸⁵	1.23	1.06-1.43	RR	147,129	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

aturated fats high intake	Kang ⁸⁶	0.87	0.78-0.96	RR	598,435	Zhu ⁹⁰	1.37	0.70-2.69	RR	7,395	NA	NA	NA	NA	NA
rotein high intake	Zhang ⁸⁷	0.98	0.89-1.07	RR	528,982	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
learing loss (ref no loss)															
resence of hearing loss	Khosravipour ⁹²	1.33	1.18-1.49	HR	5,014,271	Liang ⁹³	1.59	1.37-1.86	HR	725,847	Lawrence ⁹⁴	1.47	1.31-1.65	OR	147,148
idney function (ref eGFR ≥90 ml/min/1.73 m2)															
GFR <30	Masson ⁹⁶	1.70	1.47-1.96	RR	1,743,690	Kjaergaard ⁹⁷	1.91	1.21-3.01	HR	468,699	NA	NA	NA	NA	NA
GFR 30-60	Masson ⁹⁶	1.43	1.33-1.54	RR	2,100,733	Kjaergaard ⁹⁷	1.31	0.92-1.87	HR	468,699	NA	NA	NA	NA	NA
GFR 60-90	Masson ⁹⁶	1.10	1.03-1.19	RR	861,526	Kjaergaard ⁹⁷	1.14	1.06-1.22	HR	468,699	NA	NA	NA	NA	NA
'ain (ref no pain)															
'ain present	NA	NA	NA	NA	NA	Yuan ⁹⁸	1.26	1.18-1.35	OR	1,122,503	NA	NA	NA	NA	NA
'hysical activity (ref low)															
oderate physical activity	Lee ¹⁰⁰	0.80	0.74-0.86	RR	357,791	Iso-Markku ¹⁰³	0.80	0.77-0.84	OR	257,983	NA	NA	NA	NA	NA
igh physical activity	Lee ¹⁰⁰	0.73	0.67-0.79	RR	357,791	Lee ¹⁰⁵	0.77	0.75-0.79	RR	75,447	NA	NA	NA	NA	NA
ense of belonging/ purpose in life (ref no purpose)															
'urpose in life present	NA	NA	NA	NA	NA	Sutin ¹⁰⁷	0.76	0.72-0.79	HR	202,393	NA	NA	NA	NA	NA
leep (ref 6-8 hours)															
8 hours of sleep	Jike ¹¹⁴	1.46	1.26-1.69	RR	542,218	Fan ¹¹⁸	1.77	1.32-2.37	HR	43,412	NA	NA	NA	NA	NA
6 hours of sleep	He ¹¹⁵	1.10	0.97-1.24	RR	249,324	Fan ¹¹⁸	1.20	0.91-1.59	HR	43,412	NA	NA	NA	NA	NA
leep insomnia	Wu ¹¹⁰	1.55	1.39-1.75	RR	23,312	Shi ¹²⁰	1.17	0.95-1.43	RR	226,167	NA	NA	NA	NA	NA
leep problem/disturbance	NA	NA	NA	NA	NA	Shi ¹²⁰	1.19	1.11-1.29	RR	246,786	Hill Almeida ¹²²	1.82	1.69-1.97	RR	54,211
oking															
ref never)															
'urrent (Female)	Peters ¹²⁴	1.83	1.58-2.12	RR	3,817,289	Zhong ¹²⁸	1.30	1.18-1.45	RR	937,293	Lawrence ⁹⁴	1.35	1.00-1.81	OR	20,120
'urrent (Male)	Peters ¹²⁴	1.67	1.49-1.88	RR	3,817,289	Zhong ¹²⁸	1.30	1.18-1.45	RR	937,293	Lawrence ⁹⁴	1.35	1.00-1.81	OR	20,120
'ormer (Female)	Peters ¹²⁴	1.17	1.12-1.22	RR	3,534,330	Zhong ¹²⁸	1.01	0.96-1.06	RR	937,691	NA	NA	NA	NA	NA
'ormer (Male)	Peters ¹²⁴	1.08	1.03-1.13	RR	3,534,330	Zhong ¹²⁸	1.01	0.96-1.06	RR	937,691	NA	NA	NA	NA	NA
ocial engagement (ref not lonely, small social network)															
onely / Social isolated	Valtorta ¹³⁰	1.32	1.04-1.68	RR	105,514	Wang ¹³⁶	1.42	1.26-1.60	RR	83,765	NA	NA	NA	NA	NA
arge social network	Park ¹³¹	0.77	0.57-1.04	RR	23,576	Wang ¹³⁶	0.81	0.74-0.89	RR	87,264	NA	NA	NA	NA	NA
ress (no perceived stress)															
erceived stress	Booth ¹³⁷	1.33	1.17-1.50	HR	146,859	Franks ¹³⁸	1.44	1.07-1.95	HR	1882	NA	NA	NA	NA	NA

Legend. Abbreviations: CI = Confidence interval, dL = deciliter, eGFR = estimated Glomerulus Filtration Rate, ES = Effect Size, Est = Estimates, HR = Hazard Ratio, Kg = kilograms, LDL = Low Density Lipoprotein, LL = Late-life, mg = milligrams, ML = Midlife, mmHg = millimeters, Hg = mercury, N = number, NA = Not Applicable, OR = Odds Ratio, RR = Relative Risk, TC = total

Table 2: DALY weighted effect sizes for a composite outcome

Variable	Definition	RR (95%CI)	Normalized β
Alcohol (ref never)	>3 standard drinks/day	1.17 (0.92-1.94)	NA
	1-3 standard drinks/day	0.93 (0.85-1.01)	NA
	<1 standard drinks/day	0.73 (0.74-0.93)	-20
Blood pressure (ref <120/80 mmHg)	$\geq 140/90$ ML	2.22 (1.81-2.63)	87
	$\geq 140/90$ LL	2.17 (1.76-2.58)	85
	130-139/ 85-89	1.95 (1.73-2.21)	73
	120-129 / 80-84	1.44 (1.27-1.63)	40
BMI (ref 18.5-25 kg/m ²)	ML Obese (≥ 30)	1.47 (1.00-1.93)	42
	LL Obese (≥ 30)	1.34 (0.87-1.80)	NA
	ML Overweight (25-30)	1.25 (1.17-1.33)	24
	LL Overweight (25-30)	1.17 (1.10-1.25)	17
	ML Underweight (<18.5)	0.99 (0.99-1.10)	NA
Blood sugar (ref FPG <100mg/dL)	LL Underweight (<18.5)	0.97 (0.86-1.08)	NA
	FPG (>126)	1.69 (1.59-1.79)	57
	FPG (100-126)	1.17 (1.12-1.22)	17
Cholesterol (ref TC/LDL low)	TC high (Female)	1.02 (0.92-1.11)	NA
	TC high (Male)	1.13 (1.04-1.12)	14
	LDL	1.09 (0.85-1.39)	NA
Cognitive activity (ref none)	Leisure time cognitive activity	0.61 (0.42-0.90)	-54
Depressive symptoms (ref not present)	Present	1.36 (1.13-1.51)	34
Diet (ref high)	Vegetables high intake	0.86 (0.79-0.93)	-16
	Fruit high intake	0.83 (0.77-0.89)	-20
	Whole grain high intake	0.93 (0.87-1.00)	NA
	Dairy high intake	0.92 (0.87-0.98)	-9
	Fish high intake	0.93 (0.87-0.98)	-8
	Poultry high intake	0.97 (0.87-1.02)	NA
	Beans high intake	1.00 (0.93-1.08)	NA
	Nuts high intake	0.88 (0.80-0.97)	-14
	Red meat high intake	1.16 (1.08-1.25)	16
	Sugar Sweetened Beverage	1.28 (1.16-1.41)	27
	Sweets high intake	1.23 (1.07-1.47)	23
	Sodium high intake	1.23 (1.06-1.43)	23
	Saturated fats high intake	0.93 (0.76-1.10)	NA
Protein high intake	0.98 (0.89-1.07)	NA	
Hearing loss (ref no loss)	Present	1.37 (1.25-1.50)	35
Kidney Function (ref eGFR ≥ 90 ml/min/1.73 m ²)	eGFR <30	1.73 (1.48-1.98)	60
	eGFR 30-60	1.41 (1.30-1.53)	38
	eGFR 60-90	1.11 (1.04-1.17)	11
Pain (ref no pain)	Present	1.26 (1.18-1.35)	25
Physical activity (ref low)	Moderate physical activity	0.80 (0.74-0.85)	-25
	High physical activity	0.74 (0.68-0.79)	-34
Purpose in life (ref no purpose)	Present	0.76 (0.72-0.79)	-30
Sleep (ref 6-8 hours/no problems)	>8 hours of sleep	1.50 (1.30-1.70)	44
	<6 hours of sleep	1.11 (0.99-1.24)	NA
	Sleep insomnia	1.49 (1.33-1.64)	43
	Sleep problem/disturbance	1.41 (1.34-1.49)	38
Smoking (ref never)	Current (Female)	1.69 (1.48-1.91)	58
	Current (Male)	1.58 (1.42-1.73)	50
	Former (Female)	1.14 (1.10-1.19)	15
	Former (Male)	1.07 (1.03-1.11)	7
Social engagement (ref not lonely/ small social network)	Lonely / Social isolated	1.33 (1.06-1.61)	32
	Large social network	0.78 (0.58-0.98)	-28
Stress (ref no perceived stress)	Perceived stress	1.35 (1.17-1.52)	32

Legend. Abbreviations: β : beta-coefficient. CI: Confidence interval, dL: deciliter, eGFR: estimated Glomerulus Filtration Rate, Kg = kilograms, LDL = Low Density Lipoprotein, LL: Late-life, mg: milligrams, ML: Midlife, mmHg: millimeters, Ref: Reference, RR: relative risk, Hg: mercury, NA: Not Applicable, NS: Not Significant, TC: Total Cholesterol.